Skip to main content

Study protocol and rationale for a randomized, placebo-controlled trial of solriamfetol to treat binge eating disorder.

Author
Abstract
:

Binge eating disorder (BED) is an important public health problem associated with severe psychosocial and medical consequences for which treatment options are limited. The objective of this study is to evaluate the efficacy and tolerability of the novel dopamine and norepinephrine reuptake inhibitor (DNRI) solriamfetol in the treatment of BED.

Year of Publication
:
2021
Journal
:
Contemporary clinical trials
Volume
:
110
Number of Pages
:
106587
ISSN Number
:
1551-7144
URL
:
https://linkinghub.elsevier.com/retrieve/pii/S1551-7144(21)00323-2
DOI
:
10.1016/j.cct.2021.106587
Short Title
:
Contemp Clin Trials
Download citation